Adams Respiratory Therapeutics Inc. acquired by Reckitt Benckiser Group plc
Reckitt Benckiser Group plc acquired Adams Respiratory Therapeutics Inc., a US respiratory pharmaceuticals brand, on Jan 30, 2008.
Preliminary: The announcement date, completion date, EV/revenue, EV/EBITDA, metric basis and value notes are not yet independently verified. Sources conflict on the value basis. The EV/EBITDA is outside the usual range for comps, so treat it with caution.
Transaction summary
- Target
- Adams Respiratory Therapeutics Inc.
- Acquirer
- Reckitt Benckiser Group plc
- Seller
- -
- Announced
- 2007-12-11(unverified)
- Completed
- 2008-01-30(unverified)
- Geography
- United States
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- 100%
- First added
- 2026-08-08
- Latest update
- 2026-10-29
Value and multiples
100% enterprise value
USD 2.3B
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
6.4x
Unverified
Period not stated
Basis: FundComb estimate
EV / EBITDA
30.4x
Unverified
EBITDA basis not stated
Basis: FundComb estimate
Amounts paid and other reported values
Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.
Consideration: USD 2.3B
RTTNews reports Reckitt Benckiser agreed to buy Adams Respiratory for about $2.3 billion (£1.1 billion) in cash, or $60.00 per share for all outstanding shares; Mergr also records 2.3B USD. Exact official closing consideration was not fetched from a primary filing.
Basis
- No calculation performed. Transaction value normalized to $2.3B from public reports; spreadsheet compact value 2.2 treated as ambiguous and superseded. Multiples preserved as user-supplied from spreadsheet.
Source summary
Reckitt Benckiser Completes Acquisition Of Adams Respiratory Therapeutics
ConfirmedRTTNews reports Reckitt Benckiser completed its cash tender offer for all outstanding shares of Adams Respiratory Therapeutics at $60.00 per share, about $2.3 billion in cash; about 95.9% of shares were tendered and Adams became a wholly owned subsidiary after the follow-on merger.
Open sourceContinue your research
Related transaction comps
Biofreeze acquired by Reckitt Benckiser Group plc
2021-02-01 · Confirmed
View transaction → Same buyer / investorSSL International acquired by Reckitt Benckiser
2010-07-21 · Confirmed
View transaction → Consumer Health4E Therapeutics acquired by Eli Lilly and Company
2026-06-16 · Confirmed
View transaction → Consumer HealthTianjin TSKF Pharmaceutical Co., Ltd. acquired by Haleon plc
2025-06-27 · Confirmed
View transaction →